Company intelligence / Profile preview
Silexion Therapeutics
Jerusalem, Jerusalem, Israelsilexion.com ↗
- Ownership
- Public · SLXN
- Employees
- ~14
- Development stage
- Other
01
Overview
Silexion’s first-generation siG12D–LODER™ showed an overall survival advantage of approximately 9.3 months in a Phase 2 clinical trial for locally advanced pancreatic cancer. The next-generation candidate, SIL204, has demonstrated strong preclinical efficacy against KRAS-driven pancreatic, colorectal, and lung cancers. The company is preparing regulatory submissions and planning further clinical development in these indications.
- Therapeutic areas
- Oncology
- Modalities
- Small interfering RNA (siRNA)RNA interference (RNAi) therapyMicroparticle drug delivery system (PLG extended-release microparticles)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Evonik Corporation – collaboration on advanced siRNA formulation development to enhance drug delivery systems.
04
Financials
- Market cap
- $60.3K
- Total revenue
- $0
- Enterprise value
- $-758.7K
Beyond the preview
Go deeper on Silexion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silexion Therapeutics.